NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Vomvas D, Iconomou G, Soubasi E et al.. Assessment of sexual function in patients with cancer undergoing radiotherapy—a single centre prospective study. Anticancer Res 2012;32:657–664.
Forbat L, White I, Marshall-Lucette S, Kelly D. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2012;109:98–103.
White ID, Allan H, Faithfull S. Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy? Br J Cancer 2011;105:903–910.
Fink HA, Mac Donald R, Rutks IR et al.. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002;162:1349–1360.
Ganz PA, Greendale GA, Petersen L et al.. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054–1064.
Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009;84:139–148.
Miles CL, Candy B, Jones L et al.. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev 2007:CD005540.
Frumovitz M, Sun CC, Schover LR et al.. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428–7436.
Ganz PA, Desmond KA, Belin TR et al.. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999;17:2371–2380.
Ganz PA, Rowland JH, Desmond K et al.. Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501–514.
Lindau ST, Gavrilova N, Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol 2007;106:413–418.
Park SY, Bae DS, Nam JH et al.. Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 2007;110:2716–2725.
Rodrigues AC, Teixeira R, Teixeira T et al.. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet 2012;285:505–514.
Gershenson DM, Miller AM, Champion VL et al.. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2792–2797.
Lammerink EA, de Bock GH, Pras E et al.. Sexual functioning of cervical cancer survivors: a review with a female perspective. Maturitas 2012;72:296–304.
Syrjala KL, Kurland BF, Abrams JR et al.. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood 2008;111:989–996.
Thygesen KH, Schjodt I, Jarden M. The impact of hematopoietic stem cell transplantation on sexuality: a systematic review of the literature. Bone Marrow Transplant 2012;47:716–724.
Watson M, Wheatley K, Harrison GA et al.. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999;86:1231–1239.
- Search Google Scholar
- Export Citation
. Watson M Wheatley K Harrison GA Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999; 86: 1231– 1239.
Zantomio D, Grigg AP, MacGregor L et al.. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006;38:567–572.
Hatzichristou D, Rosen RC, Derogatis LR et al.. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7:337–348.
Rosen R, Brown C, Heiman J et al.. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
Baser RE, Li Y, Carter J. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer 2012;118:4606–4618.
Jeffery DD, Tzeng JP, Keefe FJ et al.. Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. Cancer 2009;115:1142–1153.
Flynn P, Kew F, Kisely SR. Interventions for psychosexual dysfunction in women treated for gynaecological malignancy. Cochrane Database Syst Rev 2009:CD004708.
Sutton KS, Boyer SC, Goldfinger C et al.. To lube or not to lube: experiences and perceptions of lubricant use in women with and without dyspareunia. J Sex Med 2012;9:240–250.
Biglia N, Peano E, Sgandurra P et al.. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26:404–412.
Yang EJ, Lim JY, Rah UW, Kim YB. Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecol Oncol 2012;125:705–711.
Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2010:CD007291.
Ayton RA, Darling GM, Murkies AL et al.. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351–358.
- Search Google Scholar
- Export Citation
. Ayton RA Darling GM Murkies AL A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996; 103: 351– 358.
Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother 2012;13:2131–2142.
Raghunandan C, Agrawal S, Dubey P et al.. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7:1284–1290.
Rossouw JE, Anderson GL, Prentice RL et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006:CD001500.
Brotto LA, Erskine Y, Carey M et al.. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012;125:320–325.
Duijts SF, van Beurden M, Oldenburg HS et al.. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30:4124–4133.
- Search Google Scholar
- Export Citation
. Duijts SF van Beurden M Oldenburg HS Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012; 30: 4124– 4133.
Cavalcanti AL, Bagnoli VR, Fonseca AM et al.. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int J Gynaecol Obstet 2008;102:115–119.
Yang CC, Cao YY, Guan QY et al.. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug response. Int J Impot Res 2008;20:105–110.
Alexander MS, Rosen RC, Steinberg S et al.. Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord 2011;49:273–279.
Basson R, McInnes R, Smith MD et al.. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11:367–377.
Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110:1014–1024.
Berman JR, Berman LA, Toler SM et al.. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003;170:2333–2338.
Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001;108:623–628.
Caruso S, Rugolo S, Agnello C et al.. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006;85:1496–1501.